# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-194032
Filing Date
2026-04-30
Accepted
2026-04-30 07:35:52
Documents
5
Period of Report
2026-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | 2026_pyxs-14a.htm | DEF 14A | 983830
2 | GRAPHIC | img251211442_0.jpg | GRAPHIC | 29935
3 | GRAPHIC | img251211442_1.jpg | GRAPHIC | 41024
4 | GRAPHIC | img251211442_2.jpg | GRAPHIC | 366359
5 | GRAPHIC | img251211442_3.jpg | GRAPHIC | 168893
| Complete submission text file | 0001193125-26-194032.txt |  | 1820362

Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40881 | Film No.: 26920112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)